Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Dec 13, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a substance called Indoxyl sulfate, which builds up in the blood during acute kidney injury (AKI), might affect heart and blood vessel function. Researchers want to find out if higher levels of this uremic toxin could lead to problems with blood circulation and heart health after experiencing AKI. They will measure something called pulse wave velocity (PWV), which helps assess how stiff the arteries are, three months after a patient has had an episode of AKI.

To participate in this study, you need to be over 18 years old and currently hospitalized for moderate to severe AKI without needing dialysis. However, those with severe chronic kidney disease, certain heart conditions, or other specific health issues won't be eligible. If you join the trial, you can expect to have regular assessments to track your kidney and heart health during your recovery. This research aims to improve understanding of how kidney health affects overall cardiovascular risk, which may help in developing better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 18 years old.
• • Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.
• • Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.
• • AKI from functional or organic aetiology
• Exclusion Criteria:
• • Patients with severe CKD (GFR\<45ml/min/1.73 m2) or with kidney transplants.
• • Patients with AKI from septic or obstructive aetiology.
• • Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.
• • Patients with sepsis or blood inflammation.
• • Patients with severe chronic cardia dysfunction.
• • Patients with arrhythmia or complete heart block.
• • Patients with peripheral artery occlusive disease.
• • Pregnancy.
• • Patients on palliative care.